Do you routinely consider BR (bendamustine/rituximab) as an alternative to R-CHOP as standard of care chemotherapy in an otherwise fit patient with grade 3A (not 3B) follicular lymphoma ?

Will the retrospective study (Mondello, et al. Oncologist April 2018) have any impact in your decision-making?